Current Updates on the Diagnosis and Management of Multiple Sclerosis for the General Neurologist

키워드

참고문헌 (107)

1. Duquette P, "The increased susceptibility of women to multiple sclerosis", Can J Neurol Sci, 19, pp.466~471 (1992)
2. Wallin MT, "The prevalence of MS in the United States : a population-based estimate using health claims data", Neurology, 92, pp.e1029~e1040 (2019)
3. Langer-Gould A, "Incidence of multiple sclerosis in multiple racial and ethnic groups", Neurology, 80, pp.1734~1739 (2013)
4. Bjornevik K, "Longitudinal analysis reveals high prevalence of Epstein-Barr virus associated with multiple sclerosis", Science, 375, pp.296~301 (2022)
5. Thompson AJ, "Diagnosis of multiple sclerosis : 2017 revisions of the Mc-Donald criteria", Lancet Neurol, 17, pp.162~173 (2018)
6. Bar-Or A, "Epstein-Barr virus in multiple sclerosis : theory and emerging immunotherapies : (trends in molecular medicine, 26 : 3 p : 296-310, 2020)", Trends Mol Med, 27, pp.410~411 (2021)
7. Smolders J, "Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis", PLoS One, 4, pp.e6635~ (2009)
8. Wu JS, "HLA-DRB1 allele heterogeneity influences multiple sclerosis severity as well as risk in Western Australia", J Neuroimmunol, 219, pp.109~113 (2010)
9. Horton R, "Gene map of the extended human MHC", Nat Rev Genet, 5, pp.889~899 (2004)
10. Vitkova M, "Association of latitude and exposure to ultraviolet B radiation with severity of multiple sclerosis : an international registry study", Neurology, 98, pp.e2401~e2412 (2022)
11. Wattjes MP, "2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis", Lancet Neurol, 20, pp.653~670 (2021)
12. Solomon AJ, "Misdiagnosis of multiple sclerosis : impact of the 2017 McDonald criteria on clinical practice", Neurology, 92, pp.26~33 (2019)
13. Ledesma J, "Presenting symptoms and disease severity in multiple sclerosis patients", Neurol Int, 13, pp.18~24 (2021)
14. Shams PN, "Optic neuritis : a review", Int MS J, 16, pp.82~89 (2009)
15. Wilhelm H, "The diagnosis and treatment of optic neuritis", Dtsch Arztebl Int, 112, pp.616~625 (2015)
16. Rodríguez de Antonio LA, "Non-inflammatory causes of emergency consultation in patients with multiple sclerosis", Neurologia(Engl Ed), 36, pp.403~411 (2021)
17. Optic Neuritis Study Group, "Multiple sclerosis risk after optic neuritis : final optic neuritis treatment trial follow-up", Arch Neurol, 65, pp.727~732 (2008)
18. Weinshenker BG, "The natural history of multiple sclerosis : a geographically based study. 3. Multivariate analysis of predictive factors and models of outcome", Brain, 114(Pt 2), pp.1045~1056 (1991)
19. Zecca C, "Relevance of asymptomatic spinal MRI lesions in patients with multiple sclerosis", Mult Scler, 22, pp.782~791 (2016)
20. D’Amico E, "Negative prognostic impact of MRI spinal lesions in the early stages of relapsingremitting multiple sclerosis", Mult Scler J Exp Transl Clin, 2, pp.2055217316631565~ (2016)
21. Ross Russell AL, "Lyme disease : diagnosis and management", Pract Neurol, 18, pp.455~464 (2018)
22. Djukic M, "Cerebrospinal fluid findings in adults with acute Lyme neuroborreliosis", J Neurol, 259, pp.630~636 (2012)
23. Gospe SM 3rd, "Neuromyelitis optica spectrum disorder and myelin oligodendrocyte glycoprotein associated disorder-optic neuritis: a comprehensive review of diagnosis and treatment", Eye(Lond), 35, pp.753~768 (2021)
24. Kunchok A, "Autoimmune glial fibrillary acidic protein astrocytopathy", Curr Opin Neurol, 32, pp.452~458 (2019)
25. Fritz D, "Clinical features, treatment and outcome in neurosarcoidosis : systematic review and meta-analysis", BMC Neurol, 16, pp.220~ (2016)
26. Bitik B, "Differential diagnosis of elevated erythrocyte sedimentation rate and Creactive protein levels : a rheumatology perspective", Eur J Rheumatol, 2, pp.131~134 (2015)
27. Alnajashi H, "Prevalence of antinuclear antibody in patients with multiple sclerosis : a case-control study", Egypt J Neurol Psychiatry Neurosurg, 57, pp.27~ (2021)
28. Filippatou AG, "AQP4-IgG and MOG-IgG related optic neuritis—prevalence, optical coherence tomography findings, and visual outcomes : a systematic review and meta-analysis", Front Neurol, 11, pp.540156~ (2020)
29. Chitnis T, "Neurofilament light chain serum levels correlate with 10-year MRI outcomes in multiple sclerosis", Ann Clin Transl Neurol, 5, pp.1478~1491 (2018)
30. Ostini C, "Recurrence and prognostic value of asymptomatic spinal cord lesions in multiple sclerosis", J Clin Med, 10, pp.463~ (2021)
31. McKinney AM, "Accuracy of routine fat-suppressed FLAIR and diffusionweighted images in detecting clinically evident acute optic neuritis", Acta Radiol, 54, pp.455~461 (2013)
32. Shor N, "MRI characteristics of MOG-Ab associated disease in adults:an update", Rev Neurol(Paris), 177, pp.39~50 (2021)
33. Haider L, "Cranial nerve enhancement in multiple sclerosis is associated with younger age at onset and more severe disease", Front Neurol, 10, pp.1085~ (2019)
34. Solomon AJ, "The contemporary spectrum of multiple sclerosis misdiagnosis : a multicenter study", Neurology, 87, pp.1393~1399 (2016)
35. Maggi P, "Central vein sign differentiates multiple sclerosis from central nervous system inflammatory vasculopathies", Ann Neurol, 83, pp.283~294 (2018)
36. Otto C, "Analysis of soluble interleukin-2 receptor as CSF biomarker for neurosarcoidosis", Neurol Neuroimmunol Neuroinflamm, 7, pp.e725~ (2020)
37. Smatti MK, "Viruses and autoimmunity : a review on the potential interaction and molecular mechanisms", Viruses, 11, pp.762~ (2019)
38. Dudesek A, "CLIPPERS : chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids. Review of an increasingly recognized entity within the spectrum of inflammatory central nervous system disorders", Clin Exp Immunol, 175, pp.385~396 (2014)
39. Turker H, "Visual evoked potentials in differential diagnosis of multiple sclerosis and neurobehcet’s disease", Tohoku J Exp Med, 216, pp.109~116 (2008)
40. Kruit M, "Neurovascular Imaging", pp.791~815 (2016), Springer
41. Rammohan KW, "Cerebrospinal fluid in multiple sclerosis", Ann Indian Acad Neurol, 12, pp.246~253 (2009)
42. Arun T, "Distinguishing neurosarcoidosis from multiple sclerosis based on CSF analysis : a retrospective study", Neurology, 94, pp.e2545~e2554 (2020)
43. Greene DN, "Cerebrospinal fluid myelin basic protein is frequently ordered but has little value : a test utilization study", Am J Clin Pathol, 138, pp.262~272 (2012)
44. Hassan-Smith G, "High sensitivity and specificity of elevated cerebrospinal fluid kappa free light chains in suspected multiple sclerosis", J Neuroimmunol, 276, pp.175~179 (2014)
45. Scalfari A, "Mortality in patients with multiple sclerosis", Neurology, 81, pp.184~192 (2013)
46. Marrie RA, "Vascular comorbidity is associated with more rapid disability progression in multiple sclerosis", Neurology, 74, pp.1041~1047 (2010)
47. Ribbons KA, "Male sex is independently associated with faster disability accumulation in relapse-onset MS but not in primary progressive MS", PLoS One, 10, pp.e0122686~ (2015)
48. Guillemin F, "Older age at multiple sclerosis onset is an independent factor of poor prognosis : a population-based cohort study", Neuroepidemiology, 48, pp.179~187 (2017)
49. Kavaliunas A, "Socioeconomic consequences of multiple sclerosis-A systematic literature review", Acta Neurol Scand, 143, pp.587~601 (2021)
50. Calocer F, "Socioeconomic deprivation increases the risk of disability in multiple sclerosis patients", Mult Scler Relat Disord, 40, pp.101930~ (2020)
51. Ontaneda D, "Management of acute exacerbations in multiple sclerosis", Ann Indian Acad Neurol, 12, pp.264~272 (2009)
52. Elovaara I, "Intravenous immunoglobulins are a therapeutic option in the treatment of multiple sclerosis relapse", Clin Neuropharmacol, 34, pp.84~89 (2011)
53. "Disease-modifying therapies for MS" (2023)[URL]
54. He A, "Timing of high-efficacy therapy for multiple sclerosis : a retrospective observational cohort study", Lancet Neurol, 19, pp.307~316 (2020)
55. Simonsen CS, "Early high efficacy treatment in multiple sclerosis is the best predictor of future disease activity over 1 and 2 years in a Norwegian population-based registry", Front Neurol, 12, pp.693017~ (2021)
56. Samjoo IA, "Efficacy classification of modern therapies in multiple sclerosis", J Comp Eff Res, 10, pp.495~507 (2021)
57. Jacobs LD, "Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis", Ann Neurol, 39, pp.285~294 (1996)
58. The IFNB Multiple Sclerosis Study Group, "Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial", Neurology, 43, pp.655~661 (1993)
59. "Avonex (interferon beta-1a) full prescribing information" (1996)[URL]
60. "Betaseron (interferon beta-1b) full prescribing information" (1993)[URL]
61. Dhib-Jalbut S, "Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis", Neurology, 58(8 Suppl 4), pp.S3~S9 (2002)
62. Melnikov M, "The influence of glatiramer acetate on Th17-immune response in multiple sclerosis", PLoS One, 15, pp.e0240305~ (2020)
63. Stapulionis R, "Structural insight into the function of myelin basic protein as a ligand for integrin alpha M beta 2", J Immunol, 180, pp.3946~3956 (2008)
64. "Copaxone (glatiramer acetate) full prescribing information" (1996)[URL]
65. O’Connor P, "Randomized trial of oral teriflunomide for relapsing multiple sclerosis", N Engl J Med, 365, pp.1293~1303 (2011)
66. Confavreux C, "Oral teriflunomide for patients with relapsing multiple sclerosis(TOWER) : a randomised, double-blind, placebo-controlled, phase 3 trial", Lancet Neurol, 13, pp.247~256 (2014)
67. "Aubagio (teriflunomide) full prescribing information" (2012)[URL]
68. Leist TP, "Cladribine : mode of action and implications for treatment of multiple sclerosis", Clin Neuropharmacol, 34, pp.28~35 (2011)
69. Leist TP, "Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event(ORACLE MS) : a phase 3 randomised trial", Lancet Neurol, 13, pp.257~267 (2014)
70. Giovannoni G, "A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis", N Engl J Med, 362, pp.416~426 (2010)
71. "Mavenclad (cladribine) full prescribing information" (2019)[URL]
72. Kappos L, "A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis", N Engl J Med, 362, pp.387~401 (2010)
73. "Ponvory (ponesimod) full prescribing information" (2021)[URL]
74. Singer BA, "Initiating oral fingolimod treatment in patients with multiple sclerosis", Ther Adv Neurol Disord, 6, pp.269~275 (2013)
75. Fragoso YD, "Severe exacerbation of multiple sclerosis following withdrawal of fingolimod", Clin Drug Investig, 39, pp.909~913 (2019)
76. Kasarełło K, "Mechanism of action of three newly registered drugs for multiple sclerosis treatment", Pharmacol Rep, 69, pp.702~708 (2017)
77. Prosperini L, "Dimethyl fumarate in the management of multiple sclerosis : appropriate patient selection and special considerations", Ther Clin Risk Manag, 12, pp.339~350 (2016)
78. Gold R, "Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis", N Engl J Med, 367, pp.1098~1107 (2012)
79. "Tecfidera (dimethyl fumarate) full prescribing information" (2013)[URL]
80. Naismith RT, "Diroximel fumarate demonstrates an improved gastrointestinal tolerability profile compared with dimethyl fumarate in patients with relapsing-remitting multiple sclerosis : results from the randomized, double-blind, phase III EVOLVE-MS-2 study", CNS Drugs, 34, pp.185~196 (2020)
81. "Vumerity (diroximel fumarate) full prescribing information" (2013)[URL]
82. Montalban X, "Ocrelizumab versus placebo in primary progressive multiple sclerosis", N Engl J Med, 376, pp.209~220 (2017)
83. "Ocrevus (ocrelizumab) full prescribing information" (2017)[URL]
84. Jain RW, "B cells in central nervous system disease : diversity, locations and pathophysiology", Nat Rev Immunol, 22, pp.513~524 (2022)
85. Havrdová E, "No evidence of disease activity(NEDA)analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a", Mult Scler J Exp Transl Clin, 4, pp.2055217318760642~ (2018)
86. Wolinsky JS, "Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis : a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial", Lancet Neurol, 19, pp.998~1009 (2020)
87. Golshani M, "Multiple sclerosis patients and disease modifying therapies: impact on immune responses against COVID-19 and SARS-CoV-2 vaccination", Vaccines(Basel), 10, pp.279~ (2022)
88. "Kesimpta (ofatumumab) full prescribing information" (2009)[URL]
89. Hauser SL, "Ofatumumab versus teriflunomide in multiple sclerosis", N Engl J Med, 383, pp.546~557 (2020)
90. Florou D, "Anti-CD20 agents for multiple sclerosis : spotlight on ocrelizumab and ofatumumab", Brain Sci, 10, pp.758~ (2020)
91. Polman CH, "A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis", N Engl J Med, 354, pp.899~910 (2006)
92. Berger JR, "Progressive multifocal leukoencephalopathy and natalizumab--unforeseen consequences", N Engl J Med, 353, pp.414~416 (2005)
93. "Medical information TYSABRI® (natalizumab): antiJCV antibody index and PML risk" (2021)[URL]
94. "Tysabri (natalizumab) full prescribing information" (2004)[URL]
95. "Lemtrada (alemtuzumab) full prescribing information" (2001)[URL]
96. Cohen JA, "Autologous hematopoietic cell transplantation for treatment-refractory relapsing multiple sclerosis : position statement from the American Society for blood and marrow transplantation", Biol Blood Marrow Transplant, 25, pp.845~854 (2019)
97. Muraro PA, "Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis", Nat Rev Neurol, 13, pp.391~405 (2017)
98. Dolgin E, "BTK blockers make headway in multiple sclerosis", Nat Biotechnol, 39, pp.3~5 (2021)
99. Crofford LJ, "The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapy", Expert Rev Clin Immunol, 12, pp.763~773 (2016)
100. Vermersch P, "Efficacy and safety of masitinib in progressive forms of multiple sclerosis : a randomized, phase 3, clinical trial", Neurol Neuroimmunol Neuroinflamm, 9, pp.e1148~ (2022)
101. Reich DS, "Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis : a phase 2b, randomised, double-blind, placebo-controlled trial", Lancet Neurol, 20, pp.729~738 (2021)
102. Hooijmans CR, "Remyelination promoting therapies in multiple sclerosis animal models : a systematic review and meta-analysis", Sci Rep, 9, pp.822~ (2019)
103. Cohen JA, "Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis", N Engl J Med, 362, pp.402~415 (2010)
104. Pérez-Jeldres T, "Targeting sphingosine-1-phosphate signaling in immune-mediated diseases : beyond multiple sclerosis", Drugs, 81, pp.985~1002 (2021)
105. "Gilenya (fingolimod) full prescribing information" (2010)[URL]
106. "Mayzent (siponimod) full prescribing information" (2019)[URL]
107. "Zeposia (ozanimod) full prescribing information" (2020)[URL]

관련 논문AI추천